ArticleArchives of rheumatology2025
Cardiovascular Risk Factors and Antiphospholipid Antibodies in Giant Cell Arteritis-Related Thrombosis.
Article in Archives of rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsGiant cell arteritis (GCA), a large-vessel vasculitis, is associated with increased risks of venous and arterial thrombotic events, such as visual ischemia, pulmonary embolism, and ischemic stroke. Traditional cardiovascular risk factors, such as diabetes mellitus, hypertension (HTN), and hyperlipidemia (HLD), might contribute to these events. While antiphospholipid antibodies (aPLs) are sometimes present, their role in GCA-related thrombosis remains uncertain. MATERIALS AND
methodsSeventy-five patients with biopsy-confirmed GCA were recruited, and 1-time blood samples were collected to assess for aPL. Cardiovascular risk factors (e.g., HTN, diabetes, HLD, and atrial fibrillation) at study visit and thrombotic events (pulmonary embolism, deep vein thrombosis, transient ischemic attack, stroke, and visual ischemia) throughout follow-up were abstracted from medical records. Chi-square tests and Cox models were used to evaluate associations between aPLs and these events and their risk factors.
resultsIn this cohort of 75 GCA patients, 25 (33%) had at least 1 positive aPL, with anticardiolipin IgM being the most common. Visual ischemia occurred in 19 (25%) patients. There was no significant association between visual ischemia and cardiovascular risk factors, but there was a significant association between anti-beta-2 glycoprotein I IgM and visual ischemia (P = .048) as well as between aB2GPI IgG and the development of PE/DVT (P = .0035). Overall, 16 experienced a composite thrombotic event, with only aB2GPI IgG associated with higher ischemic event rates.
conclusionAlthough aPL might be prevalent among GCA, there were minimal associations between aPL isotypes and GCA thrombotic events. Further studies are needed to confirm aPL prevalence in GCA and explore anticoagulation's potential role in patients with visual ischemia and positive aPL. Cite this article as: Hasbani GE, Crowson C, Snyder M, Warrington K, Koster M. Cardiovascular risk factors and antiphospholipid antibodies in giant cell arteritis-related thrombosis. Arch Rheumatol. 2025;40(4):422-426.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.